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Abstract
Melittin is the main effective component of bee venom and has extensive biological functions; however, serious
side effects have restricted its clinical application. Preclinical and clinical studies showed that the main adverse
events were allergic reaction and pain at the administration site. To decrease the toxicity, we prepared melittin
nano-liposomes by encapsulating melittin with poloxamer 188 and explored the inhibitory activities on liver cancer
together with biological safety. Here, we showed that melittin nano-liposomes significantly inhibited the survival of
hepatocellular carcinoma (HCC) cells in vitro and prominently suppressed the growth of subcutaneous and
orthotopic HCC transplantation tumors in vivo. It was important that it induced less inflammation and allergy in
mice compared with melittin. Overall, melittin nano-liposomes would have a better application in HCC therapy due
to its significant anti-tumor activity and better biological safety.
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Letter to the editor
Melittin is the main effective component of bee venom
and has extensive biological functions in vivo, including
anti-cancer property. To evaluate the anti-cancer activity
of melittin on hepatocellular carcinoma (HCC), a clinical
trial containing 40 HCC patients was conducted in
Yancheng Second People’s Hospital (Yancheng, China).
Patients with melittin treatment showed partial remis-
sion (PR) (n = 4, 10%), stable disease (SD) (n = 24, 60%),
and progressive disease (PD) (n = 12, 30%), and the dis-
ease control rate (CR + PR + SD) was 70%. Toxicity was
also assessable in the 40 patients. The most common ad-
verse events were pain at the administration site and
skin itch, which disappeared after melittin withdrawal
(32 grade 0, 6 grade I, and 2 grade II). This results to-
gether with other preclinical studies of melittin indicated
that it exerted a significant anti-HCC activity, while
serious side effects have restricted the clinical applica-
tion of melittin in cancer therapy [1–4]. To resolve these
problems, melittin was modified with 2% poloxamer 188
and melittin nano-liposomes were prepared (Patent
number: CN 101391098 A).
The anti-tumor activity of melittin nano-liposomes
was investigated both in vitro and in vivo models
(Additional file 1: Materials and methods). In the
current study, we found that five hepatic carcinoma
cell lines used (Bel-7402, BMMC-7721, HepG2, LM-3,
and Hepa 1-6 cells) were sensitive to melittin nano-li-
posomes, and the IC50 value was close to melittin, ranging
from 1.44 to 2.1 μM (Additional file 2: Table S1). Melittin
and melittin nano-liposomes could remarkably induce cell
apoptosis compared with vehicle or blank liposomes
(Fig. 1a and Additional file 3: Fig. S1). Western blot ana-
lysis showed that melittin nano-liposomes (2 μM) in-
creased the expression level of pro-apoptotic proteins,
such as Bax and cleaved caspase-3, and decreased anti-
apoptotic proteins, including Bcl-2 and PARP, in HepG2
cells compared with the vehicle or blank liposome group
(Fig. 1b). The apoptosis process could be partly reversed
by the caspase inhibitor Z-VAD-FMK (Fig. 1c). To assess
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Fig. 1 Melittin nano-liposomes induced apoptosis in hepatic carcinoma cells in vitro and vivo and inhibit hepatocellular carcinoma in LM-3 xenograft
tumor model. a HepG2 cells were cultured with vehicle, blank liposomes (2 μM), melittin (2 μM), or melittin nano-liposomes (2 μM) for 24 h, stained
with annexin V-FITC and PI, and analyzed by flow cytometry. b Western blot analysis of apoptosis-related proteins after HepG2 cells were treated with
vehicle, liposomes (2 μM), melittin (2 μM), or melittin nano-liposomes (2 μM) for 24 h. c HepG2 cells were pretreated with or without the caspase
inhibitor Z-VAD-FMK for 6 h and then treated with vehicle, liposomes (2 μM), melittin (2 μM), or melittin nano-liposomes (2 μM) for 24 h. Western
blot analysis of Bcl-2 and procaspase-3 was carried out subsequently. d TUNEL assay for detecting apoptosis in tumor tissues of the hepatocellular
carcinoma Hepa 1-6 orthotopic tumor model. e Western blot analysis of apoptosis-related proteins of Hepa 1-6 tumor tissues. f Live imaging photos
and the fluorescence degree of vehicle, blank liposomes (8 mg/kg), melittin (2 mg/kg), melittin nano-liposomes (2, 4, and 8 mg/kg), and sorafenib
(30 mg/kg) treated groups in the LM-3 orthotopic implanted tumor model. The data are presented as the mean ± SEM. Statistical significance was
calculated using Student’s t test (*p≤ 0.05)
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the apoptosis induced by melittin nano-liposomes in vivo,
a liver orthotopic xenograft tumor model of Hepa 1-6 cell
was established. TUNEL assay revealed that tumor tissues
of the melittin nano-liposome (2 mg/kg) group owned a
larger proportion of apoptotic cells than the control or
blank liposome groups, and the expression levels of
apoptosis-regulated proteins in tumor tissue were also de-
tected (Fig. 1d–f ). Melittin nano-liposomes also showed
significant inhibition of hepatocellular carcinoma growth
in two nude mouse models, including the HepG2 cell sub-
cutaneous xenograft model and LM-3-GFP cell orthotopic
xenograft model (Fig. 1g and Additional file 4: Fig. S2).
To evaluate the toxicity of melittin and melittin nano-
liposomes, we primarily compared the injury severity of
the mouse tails in the LM-3 model where the drugs were
administered. The tails of the melittin group showed se-
vere tissue swelling and necrosis while the tails of the




Fig. 2 Melittin nano-liposomes showed reduced toxicity in vivo. a Photos of the tails of each group at the end point of treatment. These mice
were from the LM-3 model. b TUNEL assay for detecting apoptosis in the liver tissue after mice (n = 10) were treated with vehicle, blank liposomes
(8 mg/kg), melittin (2 mg/kg), and melittin nano-liposomes (2 mg/kg) for 2 weeks. c Peripheral blood was collected from the ICR mice and analyzed
by automated hematology analyzer
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a high dose of 8 mg/kg (Fig. 2a). To further compare the
biological safety of melittin and melittin nano-liposomes,
the drugs were intraperitoneally administered to ICR
mice for 2 weeks. TUNEL assay revealed that melittin
caused slight apoptosis in hepatocytes while melittin
nano-liposomes showed lower toxicity to the liver tissue
(Fig. 2b). Meanwhile, melittin caused a decrease of
lymphocyte percentage and an increase of neutrophils in
both peripheral blood and spleen, suggesting that melit-
tin induced an inflammatory response in vivo; however,
melittin nano-liposomes showed similar lymphocyte and
neutrophil percentages as the control groups. Melittin
induced an allergic reaction with significantly increased
eosinophils and eosinophil percentage in blood, while
melittin nano-liposomes effectively prevented anaphylaxis
in the mice. Liposomes and melittin nano-liposomes also
caused an increase of splenic B lymphocytes. (Fig. 2c and
Additional file 6: Fig. S3).
In summary, our results revealed that melittin signifi-
cantly delayed HCC development with certain side effects
in clinic trial. Novel melittin nano-liposomes showed out-
standing anti-HCC potency in vitro and in vivo with a de-
creased toxicity. The results potentially have clinical
implications for melittin nano-liposomes as a promising
new drug for HCC therapy.
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Additional file 1: Materials and methods. (DOCX 24 kb)
Additional file 2: Figure S1. The effects of melittin nano-liposomes on
the proliferation and apoptosis of tumor cells. (a) Proliferation inhibiting
rates of melittin and melittin nano-liposomes on various HCC cells lines
including LM-3, Bel-7402, SMMC-7721, HepG2, and L02 cells. (b) Cell nucleus
staining by DAPI to observe the apoptosis of Bel-7402 and SMMC-7721 cells
after treated with vehicle, blank liposomes (1 μM), melittin (1 μM), or melittin
nano-liposomes (1 μM) for 24 h. (c) Fluorescence staining of Annexin V-FITC
and PI to detect the apoptosis of HepG2 cells after treatment with melittin
and Melittin nano-liposomes for 24 h and observed by fluorescence
microscope. HepG2 cells were pretreated with Z-VAD-FMK for 6 hours, and
melittin and Melittin nano-liposomes were subsequently administered at a
concentration of 2 μM. (PDF 848 kb)
Additional file 3: Figure S2. Photo of HepG2 tumors of vehicle, blank
liposomes (8 mg/kg), melittin (2 mg/kg), melittin nano-liposomes (2, 4,
and 8 mg/kg), and sorafenib (30 mg/kg) treated groups in the HepG2
subcutaneous transplanted tumor model. The data are presented as the
mean ± SEM. Statistical significance was calculated using Student’s t test
(**p ≤ 0.01; ***p≤ 0.001). (PDF 1070 kb)
Additional file 4: Figure S3. Flow cytometry analysis of splenic immune
cells including splenic T lymphocytes, neutrophil and B lymphocytes.
Spleens were stripped and grinded into cell suspension after mice were
treated with vehicle, blank liposomes (8 mg/kg), melittin (2 mg/kg) and
melittin nano-liposomes (2 mg/kg) for two weeks. (PDF 730 kb)
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